C3 glomerulopathy post kidney transplantation: A single center experience
C3G following kidney transplantation is mostly a recurrent disorder with a poor prognosis in untreated patients. Untreated recurrence has a poor prognosis with median allograft survival < 2 years. Early treatment with eculizumab may improve transplant outcomes in patients with recurrent C3G.
Authors
- Suphamai Bunnapradist (ORCID: https://orcid.org/0000-0002-1668-2005)
- Mrinalini Sarkar
- Jonathan E. Zuckerman (ORCID: https://orcid.org/0000-0001-9758-2147)
- Erik L. Lum (ORCID: https://orcid.org/0000-0001-9495-8225)
- Phuong-Thu Pham
- Meena Parakkal
- Alexis F Velazquez
- Michael A Pablos
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- World Journal of Transplantation
- Published
- 2025-02-21
- DOI
- https://doi.org/10.5500/wjt.v15.i2.101517
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00